论文部分内容阅读
目的观察护肝消癥汤、散结消痛膏配合肝动脉化疗栓塞治疗中晚期原发性肝癌的临床疗效。方法将62例中晚期原发性肝癌病例随机分为治疗组(32例)和对照组(30例)。两组均给予肝动脉化疗栓塞,每4-6周1次,均治疗3次,并配合对症治疗;治疗组同时口服护肝消癥汤、外敷散结消痛膏。两组均治疗4个月,观察近期临床疗效及治疗后患者临床症状体征、生活质量的变化情况;疗程结束后随访3年,观察0.5、1、2、3年的生存率。结果治疗组、对照组肿瘤稳定率分别为为87.5%、63.3%,组间近期临床疗效差异有统计学意义(P<0.01);治疗组治疗后肝区疼痛、腹胀、食欲不振、全身乏力明显改善,与对照组比较,差异有统计学意义(P<0.05,P<0.01);治疗组治疗后生活质量、血清白蛋白及丙氨酸氨基转移酶改善情况均明显优于对照组(P<0.05);治疗组0.5、1年、2年、3年生存率分别为81.25%、68.75%、43.75%、31.25%,对照组分别为73.33%、43.33%、20.0%、10.0%;组间比较,1、2、3年生存率差异有统计学意义(P<0.05)。结论护肝消癥汤、散结消痛膏配合肝动脉化疗栓塞治疗中晚期原发性肝癌具有较好的临床疗效。
Objective To observe the clinical curative effect of Hugan Xiaoyan decoction and Sanjiexiao Tong cream combined with transcatheter arterial chemoembolization in the treatment of advanced primary liver cancer. Methods Sixty-two cases of primary liver cancer were randomly divided into treatment group (32 cases) and control group (30 cases). Both groups were given transcatheter arterial chemoembolization, once every 4-6 weeks for 3 times, and with symptomatic treatment; the treatment group also oral Liver Decoction, topical Sanjie Xiao Tong cream. The two groups were treated for 4 months, observed the clinical efficacy and clinical symptoms and signs and quality of life of patients after treatment. The patients were followed up for 3 years after treatment to observe the survival rate of 0.5, 1, 2 and 3 years. Results The stability rates of the treatment group and the control group were 87.5% and 63.3%, respectively. There was significant difference between the two groups in the short-term clinical efficacy (P <0.01). The pain relief, abdominal distension, loss of appetite and malaise in the treatment group were obvious (P <0.05, P <0.01). After treatment, the improvement of quality of life, serum albumin and alanine aminotransferase in the treatment group were significantly better than those in the control group (P < 0.05). The survival rates at 0, 5, 1, 2 and 3 years in the treatment group were 81.25%, 68.75%, 43.75% and 31.25% respectively, and those in the control group were 73.33%, 43.33%, 20.0% and 10.0% The difference of 1, 2, 3 year survival rates was statistically significant (P <0.05). Conclusion Hugan Xiaozheng Tang and Sanjiexiao Tong cream combined with transcatheter arterial chemoembolization in the treatment of advanced primary hepatocellular carcinoma have a good clinical effect.